ArticleAntimicrobial agents and chemotherapy2021
Outpatient Fluoroquinolone Prescription Fills in the United States, 2014 to 2020: Assessing the Impact of Food and Drug Administration Safety Warnings.
Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Do fluoroquinolones increase aortic aneurysm or dissection incidence and mortality? A systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- An Updated 16-Year Pharmacovigilance Analysis of Neuropsychiatric Safety Profiles of Ciprofloxacin, Levofloxacin, and Moxifloxacin Using FAERS Data.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Impact of risk mitigation measures on oral fluoroquinolone prescribing: a multi-site population-based Canadian cohort study.Archives of public health = Archives belges de sante publique · 2026Article
- Gyrase and Topoisomerase IV as Antibacterial Targets for Gepotidacin and Zoliflodacin: Teaching Old Enzymes New Tricks.International journal of molecular sciences · 2026Review
- Efficacy and safety of a 3-day once-daily regimen of oral nafithromycin in comparison to oral moxifloxacin for the treatment of community-acquired bacterial pneumonia in adults: a phase III, randomized, double-blind controlled trial.The Lancet regional health. Southeast Asia · 2025Article
- Risk of aortic aneurysm or dissection following use of fluoroquinolones: a retrospective multinational network cohort study.EClinicalMedicine · 2025Article
- Fluoroquinolone-Mediated Tendinopathy and Tendon Rupture.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Hypoglycemia associated with fluoroquinolone: a pharmacovigilance analysis from 2014 to 2023 based on the FDA adverse event reporting system.Frontiers in medicine · 2025Article
- Comparative Analysis of Adverse Drug Reactions Associated with Fluoroquinolones and Other Antibiotics: A Retrospective Pharmacovigilance Study.Drug, healthcare and patient safety · 2025Article
- Impact of the US Food and Drug Administration warning regarding increased risk of aortic aneurysms or aortic dissections on fluoroquinolone prescribing trends.BMJ open quality · 2024Article
- Article
- Article
- Target-Mediated Fluoroquinolone Resistance inACS infectious diseases · 2024Article
- Gyrase and Topoisomerase IV: Recycling Old Targets for New Antibacterials to Combat Fluoroquinolone Resistance.ACS infectious diseases · 2024Review
- Evaluation of healthcare professionals' understanding of fluoroquinolones' safety profile, usage, and boxed warnings in Pakistan.Journal of pharmaceutical policy and practice · 2023Article
- The burden of antimicrobial resistance in the Americas in 2019: a cross-country systematic analysis.Lancet regional health. Americas · 2023Article
- Depressive and Other Adverse CNS Effects of Fluoroquinolones.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Impact of a Multifaceted Intervention on Antibiotic Prescribing for Cystitis and Asymptomatic Bacteriuria in 23 Community Hospital Emergency Departments.Hospital pharmacy · 2023Article
- Fluoroquinolone-Associated Movement Disorder: A Literature Review.Medicines (Basel, Switzerland) · 2023Review
- Treatment ofAntibiotics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The impact of United States Food and Drug Administration (FDA) safety warnings on outpatient fluoroquinolone use is unclear. Annual changes in outpatient ciprofloxacin, levofloxacin, and moxifloxacin prescription fills (IQVIA National Prescription Audit databases) were assessed using a regression model. Monthly fills during baseline (August 2014 to April 2016) and first (May 2016 to June 2018) and second FDA warning periods (July 2018 to February 2020) were compared by interrupted time series analysis. From 2015 through 2019, total fluoroquinolone fills decreased from 35,616,786 (111.1/1,000 persons) to 21,100,050 (64.3/1,000 persons) annually (10.8% annually [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.